This webinar presents recent advances using kinematic fine motor analysis to understand the effects of pharmacological agents in rodent models of neurological disorders using gait properties and fine motor performance as readouts.

Case studies are presented with data obtained from rodent in vivo efficacy models and examine disease-model-specific fine motor capabilities analysis. Examples of the effects of different pharmacological agents on fine motor and gait properties are used as a tool to evaluate non-GLP safety and tolerability of existing and novel drugs.


  • Taneli Heikkinen, PhD, Senior Scientist, Team Leader, Charles River
  • Timo Bragge, MSc, Principal Data Scientist, Charles River